Optical Coherence Tomography Has Expanded From Ophthalmology Into Cardiology and Is Now Moving Into Dentistry

The Imaging Modality Built for the Eye That the Heart Also Needed

Optical coherence tomography uses low-coherence infrared light to produce cross-sectional images of tissue microstructure at resolutions of one to fifteen micrometres, approximately ten times finer than clinical ultrasound and without the ionising radiation that X-ray and computed tomography imaging requires. The technology was developed for retinal imaging in the early 1990s because the eye's transparency to infrared light and the clinical importance of sub-millimetre retinal layer architecture in diagnosing diabetic maculopathy, age-related macular degeneration, glaucoma, and other conditions whose progression is mapped in the retinal layers that ophthalmoscopy cannot resolve created the immediate clinical application that drove OCT commercialisation. The ophthalmology OCT market, dominated by Zeiss Meditec's Cirrus platform and by Heidelberg Engineering's Spectralis, established the commercial infrastructure of OCT imaging whose global installed base now exceeds 100,000 clinical instruments in ophthalmology practices and academic eye centres, creating the clinical familiarity with OCT imaging principles that made cardiologists receptive to the technology's adaptation for intravascular coronary artery imaging.

The intravascular OCT market for coronary artery imaging, in which an OCT imaging catheter is threaded into the coronary artery over a guidewire and pulled back through the vessel while acquiring the circumferential cross-sectional images that map the coronary lumen geometry, plaque morphology, and stent apposition at the resolution that intravascular ultrasound cannot achieve, has grown from a specialised research tool into a clinically validated guidance system for percutaneous coronary intervention whose randomised controlled trial evidence of superior patient outcomes has created the reimbursement framework that commercial adoption requires. The global OCT market, valued at approximately $1.74 billion in 2026 and growing toward $2.8 billion by 2031 at a compound annual growth rate of approximately ten percent, encompasses the ophthalmology segment that remains the largest by installed base volume, the cardiology intravascular OCT segment whose procedural volume growth is the fastest revenue growth driver, and the emerging dentistry and surgical OCT applications that represent the technology's next commercial expansion frontier.

Terumo and ILUMIEN in Coronary Intervention

Abbott's ILUMIEN OPTIS and ILUMIEN IV intravascular OCT imaging systems, built on the Lightlab Imaging technology that Abbott acquired, are the commercially dominant intravascular OCT platforms whose ILUMIEN IV randomised controlled trial demonstrated superior clinical outcomes for OCT-guided percutaneous coronary intervention versus angiography-guided PCI in the ILUMIEN IV trial published in the New England Journal of Medicine, with significantly lower rates of the primary composite endpoint of cardiac death, myocardial infarction, and ischemia-driven target vessel revascularisation at two years in the OCT-guided arm. Terumo's LUNAWAVE coronary OCT imaging catheter, commercialised in Japan and expanding internationally, and the Dragonfly imaging catheter that Abbott's ILUMIEN system uses whose pullback speed and image quality create the clinical performance that the randomised evidence is built on, represent the competing commercial intravascular OCT catheter products whose procedural consumable revenue generates the recurring commercial value above the capital equipment base that imaging system sales alone provide. The combined Terumo and Abbott intravascular OCT catheter consumable market is growing at approximately fifteen percent annually as the ILUMIEN IV evidence propagates into interventional cardiology practice guidelines and as catheter reimbursement in the United States, Japan, and European markets creates the economic framework that routine intravascular OCT-guided PCI requires for broad procedural adoption beyond the academic referral centres where the clinical evidence was generated.

The coronary OCT market's expansion into the broader intravascular imaging category that also encompasses fractional flow reserve measurement and intravascular ultrasound creates the competitive dynamics that Abbott, Terumo, Philips, and Boston Scientific are navigating as the evidence base for imaging-guided PCI strengthens across multiple modalities. The OCTOBER randomised trial comparing OCT-guided versus angiography-guided PCI, published in the New England Journal of Medicine in 2022, and the ILUMIEN IV trial's subsequent two-year outcome data create the clinical evidence weight that European Society of Cardiology and American Heart Association guideline writers are incorporating into recommendations that are moving intravascular OCT from a Class IIa to a Class I indication for the complex coronary interventions where imaging guidance most clearly improves outcomes.

Dentistry and the Emerging Application

Dental OCT represents the emerging application frontier for the technology whose adaptation from ophthalmology and cardiology into dentistry exploits the same sub-millimetre tissue imaging resolution that makes OCT valuable in the eye and coronary artery to resolve the enamel, dentine, and cementum architecture that conventional dental radiography images at insufficient resolution to detect early caries, crack propagation in restored teeth, and the marginal integrity of composite restorations and ceramic crowns. The commercial dental OCT market is in its pre-commercialisation phase, with research instruments from Apixia, Nidek, and academic laboratory systems demonstrating the diagnostic capability of OCT for early caries detection, sub-surface crack visualisation, and periodontal tissue assessment that the dental clinical community is evaluating as potential replacements for or complements to conventional periapical and bitewing radiography. The regulatory pathway for dental OCT as a diagnostic medical device, the development of chairside OCT instruments whose form factor and workflow integration suit the dental operatory environment, and the clinical evidence generation from the prospective trials whose outcome data will support dental OCT's reimbursement coverage are the commercial development stages that separate the technology's current research validation from the mainstream clinical deployment that ophthalmology and cardiology OCT demonstrate is achievable once the evidence and commercial infrastructure align.

Top 10 Companies in Optical Coherence Tomography Globally

1. Zeiss Meditec (Cirrus): German medical technology company with Cirrus OCT as the most widely deployed commercial ophthalmology OCT platform; its AngioPlex OCT angiography and its global ophthalmology installed base create the OCT market leader whose retinal imaging franchise generates the recurring software and consumable revenue that underpins the ophthalmology OCT commercial model.
2. Abbott (ILUMIEN IV): US medical device company with ILUMIEN OPTIS and ILUMIEN IV coronary OCT systems backed by ILUMIEN IV randomised trial evidence; its New England Journal of Medicine publication demonstrating OCT-guided PCI superiority and its Dragonfly imaging catheter create the commercial intravascular OCT leader whose clinical evidence is reshaping interventional cardiology practice.
3. Heidelberg Engineering (Spectralis): German ophthalmology imaging company with Spectralis OCT and OCT angiography; its confocal scanning laser ophthalmoscope integration and its research-grade imaging performance create the ophthalmic OCT platform preferred by academic retinal specialists and clinical trial imaging centres whose publications advance OCT's clinical evidence base.
4. Terumo (LUNAWAVE): Japanese medical device company with LUNAWAVE coronary OCT imaging catheter commercialised in Japan and expanding internationally; its catheter engineering expertise and its Japanese interventional cardiology market relationships create the competing intravascular OCT catheter whose pullback imaging system serves the Japanese market where OCT-guided PCI adoption is among the highest globally.
5. Topcon (Maestro): Japanese optical and medical device company with Maestro swept-source OCT for ophthalmology; its wide-field swept-source OCT imaging and its optometry market relationships create the ophthalmology OCT commercial position in the primary eye care and optometry channel whose OCT adoption for glaucoma and diabetic retinopathy screening is expanding the total OCT market beyond specialist retinal centres.
6. Nidek: Japanese ophthalmic instrument company with RS-3000 and Mirante OCT platforms for retinal imaging; its ophthalmic instrument manufacturing heritage and its optometry and ophthalmology distribution create the Japanese OCT company whose global distribution reaches the mid-market ophthalmology practice segment that the premium Zeiss and Heidelberg systems do not fully serve at competitive price points.
7. Philips (Coronary Physiology): Dutch medical technology company with intravascular imaging and coronary physiology products complementing OCT in the interventional cardiology workflow; its iFR instantaneous wave-free ratio physiology and its IVUS imaging create the competing intravascular imaging commercial position whose integration with OCT in the hybrid IVUS-OCT catheter development represents the next-generation intravascular imaging technology direction.
8. Canon Medical Systems: Japanese medical imaging company with retinal OCT systems from its Optopol acquisition; its global medical imaging distribution and its OCT technology portfolio create the medical imaging company's ophthalmology OCT commercial position in the hospital-based ophthalmology market where Canon Medical's brand and service infrastructure support adoption.
9. Optos (Nikon): UK ultra-widefield retinal imaging company with OCT integration into its ultra-widefield retinal imaging platform; its panoramic retinal imaging and its OCT integration create the widefield OCT retinal imaging system whose single-capture ultra-widefield retinal view with OCT cross-section creates the examination efficiency that high-volume retinal screening programmes value.
10. Apixia: US dental imaging company with dental OCT development for early caries detection and restorative margin assessment; its dental imaging background and its OCT adaptation for the chairside dental environment create the dental OCT pioneer whose commercial product development represents the technology's transition from dental school research to clinical practice deployment.